Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
2223results about "Tetrapeptide ingredients" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Monomethylvaline compounds capable of conjugation to ligands
ActiveUS20050238649A1Improve bioavailabilityImprove compoundAntibacterial agentsBiocideD-norephedrineBiochemistry
Owner:SEAGEN INC
P-amidobenzylethers in drug delivery agents
InactiveUS20030130189A1Decrease in drug activityImprove stabilityTetrapeptide ingredientsTripeptide ingredientsEtherDiluent
Compounds of the formulas LAn-Z-X-WwD and BZ-X-WwD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-immolative group; n is an integer of 0 or 1; and w is an integer of 0 or 1, and compositions of said compounds with pharmaceutically acceptable carrier, diluent and / or excipient, and methods of delivery the drug D via the compounds.
Owner:SEAGEN INC
Peptides as NS3-serine protease inhibitors of hepatitis C virus
InactiveUS7012066B2Organic active ingredientsDigestive systemSerine Protease InhibitorsHepatitis C virus
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Owner:DENDREON PHARMA INC +1
p-Amidobenzylethers in drug delivery agents
Compounds of the formulaeLAn-Z-X—WwD and BZ-X—WwDwherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide residue; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-immolative group; n is an integer of 0 or 1; and w is an integer of 0 or 1, and compositions of said compounds with pharmaceutically acceptable carrier, diluent and / or excipient, and methods of delivery the drug D via the compounds.
Owner:SEAGEN INC
Topical formulations and methods of use
InactiveUS20060216251A1Treating and protectingLow elastic modulusBiocideCosmetic preparationsWrinkle skinDihydrolipoic acid
A topical composition comprising a lipoic acid, a carnitine, and a carnosine in a suitable vehicle for topical application and a method for treating skin is provided. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles and loss of elasticity. Preferred components include R-lipoic acid or R-dihydrolipoic acid, acetyl-1-carnitine, and 1-carnosine.
Owner:TRACIE MARTYN INT
(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
The present invention discloses the compound of Formula 3 as an inhibitor of HCV protease, as well as methods for preparing the compound. In another embodiment, the invention discloses pharmaceutical compositions comprising the compound as well as methods of using them to treat disorders associated with the HCV protease.
![(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease](https://images-eureka.patsnap.com/patent_img/68ff82f9-3880-45b4-9833-0144a15a0351/US20050249702A1-20051110-C00001.png "(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease")
![(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease](https://images-eureka.patsnap.com/patent_img/68ff82f9-3880-45b4-9833-0144a15a0351/US20050249702A1-20051110-C00002.png "(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease")
![(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease](https://images-eureka.patsnap.com/patent_img/68ff82f9-3880-45b4-9833-0144a15a0351/US20050249702A1-20051110-C00003.png "(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease")
Owner:SCHERING CORP
Hepatitis C virus inhibitors
ActiveUS7041698B2Inhibit functioningEffective treatmentBiocideTetrapeptide ingredientsHcv hepatitis c virusPharmaceutical drug
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Owner:BRISTOL MYERS SQUIBB CO
Substituted cycloalkyl P1′ hepatitis C virus inhibitors
InactiveUS6878722B2Inhibit functioningEffective treatmentBiocideDipeptide ingredientsHepacivirusVirology
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Owner:BRISTOL MYERS SQUIBB CO
Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
Owner:VERTEX PHARMA INC
Methods and compositions for treatment of free radical injury
InactiveUS20060121016A1Reduction of tissue level oxidative damage toBiocideDipeptide ingredientsAntioxidantCell membrane
Therapeutic methods and compositions useful for the prevention and / or treatment of cellular membrane damage leading to or resulting from peroxidation of the cellular membrane and a breakdown of the barrier function of the cellular membrane. A therapeutic composition includes a combination of a membrane sealing sealing surfactant and a cofactor treatment consisting of an antioxidant and a cellular energy store. To affect this goal, the permeability of damaged cellular membranes is reestablished by the membrane sealing surfactant, effectively “sealing” the injured membranes. To facilitate rapid tissue recovery, cellular energy levels can be reestablished through addition of a cellular energy source such as, for example, MgCl2-ATP which, serves a further dual benefit of improving the cellular ion balance. Addition of an antioxidant eliminates the generation of Reactive Oxygen intermediates and enhances the metabolism of free radicals.
Owner:MAROON BIOTECH
Active agent delivery systems and methods for protecting and administering active agents
The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.
Owner:TAKEDA PHARMA CO LTD
Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors
Peptides of general formula (I): R1AA1-AA2-AA3-AA4-R2 stereoisomers thereof, mixtures thereof or the cosmetically or pharmaceutically acceptable salts thereof, a method for obtaining them, cosmetic or pharmaceutical compositions containing them, and their use for the treatment and / or care of those conditions, disorders and / or pathologies of the skin, mucosae and / or scalp resulting from matrix metalloproteinases (MMP) overexpression or an increase in the MMP activity.
Owner:LIPOTEC SA
Compounds for enzyme inhibition
ActiveUS20050245435A1Inhibiting and reducing HIV infectionAffecting levelBiocideNervous disorderEnzyme inhibitionAziridine
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Owner:ONYX THERAPEUTICS
Β-glucuronide-linker drug conjugates
ActiveUS8039273B2Kill or inhibit the proliferation of the tumor cellsTetrapeptide ingredientsImmunoglobulinsOrganic chemistryGlucuronide
Owner:SEAGEN INC
Compositions containing mixtures of tetrapeptides and tripeptides
ActiveUS6974799B2Reducing visible sign of agingImprove stateCosmetic preparationsToilet preparationsPersonal careTetrapeptide
Pharmaceutical, personal care and cosmetic compositions containing a tripeptide and a tetrapeptide are useful for treating visible signs of aging including wrinkles, stretch marks and dark circles.
Owner:SEDERMA SA
Detection and treatment of autoimmune disorders
Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing the involving a PD1 ligand.
Owner:SEATTLE CHILDRENS HOSPITAL
Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
InactiveUS20070274951A1Improve bioavailabilityBiocideTetrapeptide ingredientsEnzyme inhibitorPolymerase inhibitor
Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of at least one HCV protease inhibitor and at least one HCV polymerase inhibitor but not HCV-796; for concurrent or consecutive administration in treating or ameliorating one or more symptoms of HCV, or disorders associated with HCV in a subject in need thereof.
Owner:SCHERING CORP
Active agent delivery systems and methods for protecting and administering active agents
Owner:TAKEDA PHARMA CO LTD
Method and composition to reduce cancer incidence
InactiveUS6090414AReduce distractionsInhibition formationBiocideTetrapeptide ingredientsHydroxybenzoate EthersS oxidation
The five component composition consisting essentially of: (1) Water soluble antioxidant vitamin C or ascorbic acid, or any of its forms or derivatives, or mixtures thereof. (2) Oil soluble antioxidant vitamin E or Alpha-tocophorol, or any of its forms or derivatives, or mixtures thereof. (3) The element selenium, or a chemical (or composition) containing it, or mixtures thereof. The most preferred chemical containing selenium is dimethyl selenide and mixtures thereof. The words "dimethyl selenide" here and hereinafter mean dimethyl selenide and / or it's oxidation products, including dimethyl selenoxide. (4) A sulfur amino acid, in any form, or a sulfur peptide, or a sulfur protein, or any of their derivatives, or mixtures thereof. The mixture of methionine and cysteine, which contains as impurities some seleno-methionine and some selenocysteine, is preferred,-the tripeptide glutathione containing cysteine is also preferred. (5) Another antioxidant, other than vitamin C and other than vitamin E, which is synthetic or natural and water soluble or oil soluble, or a mixture of such antioxidants, or a combination of such forms thereof. The mixtures of butylated hydroxyanisole and ethoxyquin is preferred.
Owner:LIFE SCI LAB
Compositions and methods for treatment of eye disorders
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Owner:NOVARTIS PHARM CORP
Quinoxalinyl tripeptide hepatitis C virus inhibitors
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
InactiveUS20050123628A1Reduce oxidative stressReduce lipid peroxidationBiocideDipeptide ingredientsChronic viral hepatitis CLipid peroxidation
The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.
Owner:ZABRECKY GEORGE
Methods of imaging and treatment
InactiveUS7329402B2For signal receptionDecreasing background tissue signalTetrapeptide ingredientsEchographic/ultrasound-imaging preparationsThrombusTarget tissue
Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.
Owner:IMARX PHARM CORP
Anti-tumor agents
InactiveUS6890904B1Prevent proliferationMinimize potentialDipeptide ingredientsTetrapeptide ingredientsAbnormal tissue growthLymphatic Spread
A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
Owner:DARA BIOSCI
Method of treating multiple sclerosis
InactiveUS20070161566A1Relieve symptomsReducing MRI-monitored disease activity and burden of a patientTetrapeptide ingredientsDepsipeptidesEnhancing LesionSubcutaneous injection
This invention provides a method of alleviating a symptom of a patient suffering from a relapsing form of multiple sclerosis which comprises periodically administering to the patient by subcutaneous injection a single dose of a pharmaceutical composition comprising 40 mg of glatiramer acetate so as to thereby alleviate the symptom of the patient. This invention also provides a method of reducing Gd-enhancing lesions in the brain and a pharmaceutical composition in a unit dosage.
Owner:TEVA PHARMA IND LTD
Enzyme-activated anti-tumor prodrug compounds
Disclosed are enzyme-activated anti-tumor and anti-metastatic prodrug compounds. The specific enzymes are collagenase(IV) and elastase. Also disclosed are methods of making and using such compounds.
Owner:BOEHRINGER INGELHEIM PHARMA INC
Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
InactiveUS20140271923A1Good for healthImproving well-beingHeavy metal active ingredientsBiocideSide effectPolycystic ovary
Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric. The present invention further relates to a method of identifying agents, compounds or drugs useful in preventing or treating CDCP related diseases and conditions as well as other disorders, diseases and conditions treatable or preventable by the same agents, compounds or drugs.
Owner:REID CHRISTOPHER BRIAN
Immunoregulator
InactiveUS20020064501A1Prevent rejectionImmunological interactionMicrobiological testing/measurementTetrapeptide ingredientsAutoimmune responsesAllergy
The invention relates to the field of immunology. Specifically, the invention relates to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides for an immunoregulator (IR), use of an IR in preparing a pharmaceutical composition for treating an immune-mediated disorder and a method for treating an immune-mediated disorder.
Owner:BIOTEMPT
Appetite satiation and hydration beverage
InactiveUS20050276839A1Sufficient nutritional valueAvoid malnutritionBiocideTetrapeptide ingredientsBetaineAdditive ingredient
Appetite satiation and hydrating beverages and methods of delivering appetite satiation ingredients and nutrients are disclosed. According to one embodiment of the invention, the appetite satiationhydrating beverage comprises at least one complex carbohydrate, at least one chelated electrolyte, hoodia gordonii cactus, gymnema sylvestre, betaine and piperine.
Owner:RIFKIN CALMAN H
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com